Abstract: The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 5.9, 30.2, and 31.2 degrees; or a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 3.7, 5.9, and 26.6 degrees. Also provided herein are methods of preparing the polymorphic forms of sodium benzoate and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease).
Type:
Grant
Filed:
March 7, 2017
Date of Patent:
July 2, 2019
Assignee:
SyneuRx International (Taiwan) Corp.
Inventors:
Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
Abstract: The disclosure provides for methods for reducing dust by treating a seed with a dust reducing composition described herein. The disclosure also provides for methods of reducing exposure to vacuum planter dust released during seed planting by applying a composition described herein to a seed. Methods for increasing seed lubricity by coating a seed with a composition described herein are also provided for. Compositions and seeds useful in these methods are also described.
Type:
Grant
Filed:
February 8, 2018
Date of Patent:
June 18, 2019
Assignee:
Bayer CropScience LP
Inventors:
Yaodong Huang, William Hanson, Philip M. Mathew, Smita Patel, Justin Eldridge
Abstract: The present invention provides a composition suitable for forming an intramuscular implant. It comprises a biodegradable thermoplastic polymer of polylactic acid (PLA), DMSO and an aromatase inhibitor compound. The invention also provides a kit suitable for the in situ formation of the composition and its use as a medicine for treating cancer, especially breast cancer.
Abstract: A plant activator composition increases the concentration of terpenes a terpinoids in aromatic plant oils, and hence resulting in an increased concentration of terpene and terpinoids in the harvested dried plant or fruit. The composition contains one of more bio-active compounds that are optionally extracted from plants selected from one or more of the group consisting of mango, citrus (including grapefruit), Catharanthus roseus and Pelargonium odoratissimum, but alternatively may include one or more synthetic compounds selected from the group consisting of geranyl acetate, geraniol, beta-sitosterol, alpha-amyrin, beta amyrin, carotenoid, geranyl acetate, alpha-humulene, mevalonate kinase and geranyl. Depending on the type of plant being treated, the formulation is added during watering and feeding in optimum doses during the vegetative growth, flowering, and fruit set and/or swell stages.
Abstract: Provided herein are anhydrous compositions that include at least one viscosity increasing agent, at least one organic solvent and at least one humectant. Such compositions may also include at least one active pharmaceutical ingredient (API) and/or at least one water repellant. Related compositions, methods and kits are also provided.
Abstract: Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.
Type:
Grant
Filed:
May 25, 2017
Date of Patent:
April 23, 2019
Assignee:
SUPERNUS PHARMACEUTICALS, INC.
Inventors:
Michael L. Vieira, Austin B. Huang, Padmanabh P. Bhatt
Abstract: A method of treating insulin resistance includes administering to a subject a pharmaceutical composition comprising diethyl azelate. For example, a method of treating insulin resistance includes orally administering to a subject a pharmaceutical composition that includes diethyl azelate at a dosage range from about 0.1 mg/kg/day to about 10 mg/kg/day.
Abstract: Injectable depot compositions, comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.
Type:
Grant
Filed:
July 11, 2018
Date of Patent:
February 5, 2019
Assignee:
LABORATORIOS FARMACEUTICOS ROVI, S.A.
Inventors:
Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
Abstract: Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is supplemented by zinc, and the combination is effective to promote a swallowing reflex. The composition comprising the combination of cinnamaldehyde and zinc can be used in a method to treat dysphagia and/or prevent aspiration pneumonia from dysphagia. In an embodiment, the composition comprising cinnamaldehyde is administered to a human. The composition comprising cinnamaldehyde may be a medicament, a food product or a supplement to a food product.
Type:
Grant
Filed:
March 17, 2015
Date of Patent:
January 29, 2019
Assignee:
Nestec S.A.
Inventors:
Stephanie Michlig Gonzalez, Jenny Meylan Merlini, Adam Burbidge, Johannes Le Coutre
Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved since the first day up to at least 14 days or more even up to at least four weeks.
Type:
Grant
Filed:
April 4, 2018
Date of Patent:
January 22, 2019
Assignee:
LABORATORIOS FARMACEUTICOS ROVI S.A.
Inventors:
Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
Abstract: A hemostatic tissue sealant sponge and a spray for acute wounds are disclosed. The sponge comprises hydrophobically modified polymers that anchor themselves within the membrane of cells in the vicinity of the wound. The seal is strong enough to substantially prevent the loss of blood inside the boundaries of the sponge, yet weak enough to substantially prevent damage to newly formed tissue upon recovery and subsequent removal of the sponge. In examples, the polymers inherently prevent microbial infections and are suitable for oxygen transfer required during normal wound metabolism. The spray comprises hydrophobically modified polymers that form solid gel networks with blood cells to create a physical clotting mechanism to prevent loss of blood. In an example, the spray further comprises at least one reagent that increases the mechanical integrity of the clot. In another example, the reagent prevents microbial infection of the wound.
Type:
Grant
Filed:
January 19, 2016
Date of Patent:
January 15, 2019
Assignees:
University of Maryland, College Park, University of Maryland, Baltimore
Inventors:
Matthew Dowling, John Hess, Grant Bochicchio, Srinivasa Raghavan
Abstract: The present invention relates to a composition, in particular a solid pharmaceutical composition comprising a compound having the formula I, as a free base or a salt thereof, and a mixture comprising a vehicle and a non-ionic surfactant in an amount sufficient to achieve solubilization of compound (I); and typically wherein the composition is coated with an enteric coating. Such composition is particularly useful in treatment of cancer.
Abstract: Many active agents, such as insecticides, herbicides and fungicides are relatively insoluble in aqueous media. In order to apply them efficiently to crops it is thus necessary to formulate them in a manner that facilitates their dilution in the water based spray media used in practice, by the farmer or contract spray operator. The present invention relates to aqueous dispersions of active agents such as insecticides, herbicides and fungicides, in particular such dispersions in which the particles are of sub-micron diameter.
Abstract: Immune function of a plant can be modulated by administering a composition comprising beta glucan, where the beta glucan includes unbranched beta-(1,3)-glucan. Such unbranched beta-(1,3)-glucan can be obtained from Euglena, including heterotrophically grown Euglena. The unbranched beta-(1,3)-glucan can be in the form of paramylon and/or can be part of algae meal. The composition can further include a fertilizer, a pesticide, a fungicide, a bactericide, combinations thereof, as well as one or more various plant immune system modulators other than beta glucan. The wellbeing of the plant seed, seedling, mature plant, or harvested plant product can accordingly be improved.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
November 20, 2018
Assignee:
KEMIN INDUSTRIES, INC.
Inventors:
Robert B. Levine, Geoffrey P. Horst, Jeffrey R. LeBrun
Abstract: Process for obtaining fluoride-doped citrate-coated amorphous calcium phosphate nanoparticles. This material has applications in biomedicine due to its biodegradability and bioactivity; it also promotes cell adhesion and osteogeneration. In dentistry, it may be used in toothpastes, mouthwashes, chewing gums, gels and fluoride varnishes as a remineralising agent of dentine and enamel. It is based on two solutions formed by calcium chloride and sodium citrate on the one hand, and by sodium monohydrogenophosphate and sodium carbonate with a fluoride compound on the other, which are mixed at room temperature. The process is eco-efficient and eco-friendly, as it does not leave any acid residue; it consists of a single stage and it is the first time that an amorphous calcium phosphate coated with citrate and doped with fluoride, which enhances its remineralising action, is obtained.
Type:
Grant
Filed:
July 21, 2015
Date of Patent:
October 23, 2018
Assignee:
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Inventors:
Jose Manuel Delgado Lopez, Jaime Gomez Morales, Raquel Fernandez Penas, Michele Iafisco, Anna Tampieri, Silvia Panseri
Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved since the first day up to at least 14 days or more even up to at least four weeks.
Type:
Grant
Filed:
November 30, 2012
Date of Patent:
October 2, 2018
Assignee:
LABORATORIOS FARMACEUTICOS ROVI, S.A.
Inventors:
Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
Abstract: Stable non-alcoholic transdermal hydrogel of dexibuprofen was prepared by using a simple manufacturing process, and the experimental trials showed that the pH modifying agent, antioxidant and water miscible solvent are the essential excipients to obtain stable non-alcoholic transdermal hydrogel of dexibuprofen. The dexibuprofen hydrogel prepared using carbopol as a gelling polymer produced an opaque gel, whereas hydrogel prepared using hyroxypropyl methylcellulose (HPMC) as a gelling polymer produced a transparent gel. There was no significant changes observed with respect to physical description, pH, assay and particularly to the related substance values when the hydrogels were subjected to the stability study at accelerated condition (40° C./75% RH) for 3 months in laminated tubes.
Type:
Grant
Filed:
August 12, 2015
Date of Patent:
October 2, 2018
Assignee:
Strides Shasun Limited
Inventors:
Jeffrey Stuart Bergman, Sampathkumar Devarajan, Selvakumar Ramalingam, Anandsenthil Vel Palanisamy
Abstract: Injectable depot compositions, comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.
Type:
Grant
Filed:
November 30, 2012
Date of Patent:
August 28, 2018
Assignee:
LABORATORIOS FARMACEUTICOS ROVI, S.A.
Inventors:
Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
Abstract: The present invention provides tooth-whitening compositions comprising a bleaching agent and a basic amino acid, together with devices for application thereof, and methods of use therefor.
Type:
Grant
Filed:
February 6, 2009
Date of Patent:
March 20, 2018
Assignee:
Colgate-Palmolive Company
Inventors:
Michael Prencipe, Richard Scott Robinson, Rajnish Kohli, Richard J. Sullivan
Abstract: The present invention generally relates to high residual effect and/or low off-site movement anionic herbicide formulations and, more particularly, auxin herbicide formulations. Generally, the formulations of the present invention include an anionic herbicide (e.g., an auxin herbicide), a particulate sorbent (e.g., silica), a cationic surfactant, and water.